Burning Rock Biotech Q2 Earnings and Strategic Shift
Company Announcements

Burning Rock Biotech Q2 Earnings and Strategic Shift

Burning Rock Biotech (BNR) has released an update.

Burning Rock Biotech reported a decrease in total revenues by 7.3% in the second quarter of 2024 compared to the same period in 2023, primarily due to a strategic shift from central-lab to in-hospital based testing, which saw an 11.2% revenue increase. Despite a dip in gross profit and an overall net loss, the company managed to reduce operating expenses through budget control and headcount reduction. The company remains a key player in next generation sequencing for precision oncology, with partnerships and study results presented at recent conferences.

For further insights into BNR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyBurning Rock Biotech, Dizal announce NMPA approval for sunvozertinib CDx
TipRanks Auto-Generated NewsdeskBurning Rock Biotech Announces Executive Changes
TheFlyBurning Rock Biotech CFO Leo Li resigns
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App